R. Leduc

发表

The role of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia

I. Ghobrial, X. Leleu, N. Ramaiya, 2011, American journal of hematology.

Novel agents in the treatment of Waldenström's macroglobulinemia.

S. Treon, A. Roccaro, A. Sacco, 2007, Clinical lymphoma & myeloma.

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

A. Jakubowiak, R. Vij, N. Munshi, 2011, The Lancet. Oncology.

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia

P. Richardson, S. Rodig, L. Varticovski, 2010, Clinical Cancer Research.

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

P. Richardson, S. Ansell, A. Dispenzieri, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.

P. Richardson, D. DeAngelo, E. Jacobsen, 2008 .

Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM)

P. Richardson, S. Treon, I. Ghobrial, 2008 .

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

P. Richardson, S. Treon, I. Ghobrial, 2010, American journal of hematology.

Phytochemical variation in Canadian Hydrastis canadensis L (goldenseal) and the in vitro inhibition of human cytochrome P450-mediated drug metabolism by H canadensis and other botanicals

R. Leduc, R. I. Leduc, 2007 .

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

P. Richardson, A. Dispenzieri, D. DeAngelo, 2009 .

Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia.

P. Richardson, I. Ghobrial, S. Padmanabhan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia

S. Treon, A. Roccaro, I. Ghobrial, 2008, Leukemia & lymphoma.

The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia

I. Ghobrial, X. Leleu, W. Xie, 2010, Clinical Cancer Research.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2009 .

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

P. Richardson, S. Treon, I. Ghobrial, 2009 .

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

R. Vij, N. Munshi, J. Laubach, 2009 .

Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma

R. Vij, N. Munshi, J. Laubach, 2008 .

Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib

A. Jakubowiak, R. Vij, N. Munshi, 2010 .

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

P. Richardson, S. Ansell, A. Dispenzieri, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.